The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
COBRA combination therapy in patients with early rheumatoid arthritis: Long‐term structural benefits of a brief intervention
Open accessAbstract
Objective: The Combinatietherapie Bij Reumatoide Artritis (COBRA) trial demonstrated that step‐down combination therapy with prednisolone, methotrexate, and sulfasalazine (SSZ) was superior to SSZ monotherapy for suppressing disease activity and radiologic progression of rheumatoid arthritis (RA). The current study was conducted to investigate whether the benefits of COBRA therapy were sustained over time, and to determine which baseline factors could predict outcome. Methods: All patients had participated in the 56‐week COBRA trial. During followup, they were seen by their own rheumatologists and were also assessed regularly by study nurses; no treatment protocol was specified. Disease activity, radiologic damage, and functional ability were the primary outcome domains. Two independent assessors scored radiographs in sequence according to the Sharp/van der Heijde method. Outcomes were analyzed by generalized estimating equations on the basis of intent‐to‐treat, starting with data obtained at the last visit of the COBRA trial (56 weeks after baseline). Results: At the beginning of followup, patients in the COBRA group had a significantly lower mean time‐averaged 28‐joint disease activity score (DAS28) and a significantly lower median radiologic damage (Sharp) score compared with those in the SSZ monotherapy group. The functional ability score (Health Assessment Questionnaire [HAQ]) was similar in both groups. During the 4–5 year followup period, the time‐averaged DAS28 decreased 0.17 points per year in the SSZ group and 0.07 in the COBRA group. The Sharp progression rate was 8.6 points per year in the SSZ group and 5.6 in the COBRA group. After adjustment for differences in treatment and disease activity during followup, the between‐group difference in the rate of radiologic progression was 3.7 points per year. The HAQ score did not change significantly over time. Independent baseline predictors of radiologic progression over time (apart from treatment allocation) were rheumatoid factor positivity, Sharp score, and DAS28. Conclusion: An initial 6‐month cycle of intensive combination treatment that includes high‐dose corticosteroids results in sustained suppression of the rate of radiologic progression in patients with early RA, independent of subsequent antirheumatic therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longitudinal Data Analysis for Discrete and Continuous Outcomes
Zeger, S. L., & Liang, K.-Y. (1986) · Biometrics · doi:10.2307/2531248 · Cited by 7,764
Prevoo, M. L. L., Van'T Hof, M. A., Kuper, H. H., Van Leeuwen, M. A., Van De Putte, L. B. A., & Van Riel, P. L. C. M. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380107 · Cited by 6,243
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
Lipsky, P. E., van der Heijde, D. M. F. M., St. Clair, E. W., Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Weisman, M., Emery, P., Feldmann, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432202 · Cited by 2,996
Self-citationA Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
Bathon, J. M., Martin, R. W., Fleischmann, R. M., Tesser, J. R., Schiff, M. H., Keystone, E. C., Genovese, M. C., Wasko, M. C., Moreland, L. W., Weaver, A. L., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432201 · Cited by 1,730
Boers, M., Verhoeven, A. C., Markusse, H. M., van de Laar, M. A., Westhovens, R., van Denderen, J. C., van Zeben, D., Dijkmans, B. A., Peeters, A. J., Jacobs, P., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)01300-7 · Cited by 1,073
Self-citationMöttönen, T., Hannonen, P., Leirisalo-Repo, M., Nissilä, M., Kautiainen, H., Korpela, M., Laasonen, L., Julkunen, H., Luukkainen, R., Vuori, K., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)08513-4 · Cited by 865
The Effect of Glucocorticoids on Joint Destruction in Rheumatoid Arthritis
Kirwan, J. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199507203330302 · Cited by 817
Van Der Heijde, D., Van Riel, P., Gribnau, F., Nuver-Zwart, I., & Van De Putte, L. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92442-2 · Cited by 556
Self-citationFactors predicting response to treatment in rheumatoid arthritis: The importance of disease duration
Anderson, J. J., Wells, G., Verhoeven, A. C., & Felson, D. T. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200001)43:1<22::aid-anr4>3.0.co;2-9 · Cited by 503
Self-citationvan der Heide, A., Jacobs, J. W. G., Bijlsma, J. W. J., Heurkens, A. H. M., van Booma-Frankfort, C., van der Veen, M. J., Haanen, H. C. M., & Hofman, D. M. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-8-199604150-00001 · Cited by 480
Cited by
Breedveld, F. C., Weisman, M. H., Kavanaugh, A. F., Cohen, S. B., Pavelka, K., Vollenhoven, R. V., Sharp, J., Perez, J. L., & Spencer‐Green, G. T. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21519 · Cited by 1,785
Smolen, J. S., Landewé, R., Breedveld, F. C., Buch, M., Burmester, G., Dougados, M., Emery, P., Gaujoux-Viala, C., Gossec, L., Nam, J., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204573 · Cited by 1,763
Self-citationGoekoop‐Ruiterman, Y. P. M., De Vries‐Bouwstra, J. K., Allaart, C. F., Van Zeben, D., Kerstens, P. J. S. M., Hazes, J. M. W., Zwinderman, A. H., Ronday, H. K., Han, K. H., Westedt, M. L., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21405 · Cited by 1,460
Self-citationPharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347
St. Clair, E. W., van der Heijde, D. M. F. M., Smolen, J. S., Maini, R. N., Bathon, J. M., Emery, P., Keystone, E., Schiff, M., Kalden, J. R., Wang, B., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20568 · Cited by 1,143
Self-citationFelson, D. T., Smolen, J. S., Wells, G., Zhang, B., van Tuyl, L. H. D., Funovits, J., Aletaha, D., Allaart, C. F., Bathon, J., Bombardieri, S., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30129 · Cited by 1,022
Self-citationKlareskog, L., Catrina, A. I., & Paget, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60008-8 · Cited by 787
Combe, B., Landewe, R., Lukas, C., Bolosiu, H. D., Breedveld, F., Dougados, M., Emery, P., Ferraccioli, G., Hazes, J. M. W., Klareskog, L., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.044354 · Cited by 786
Felson, D. T., Smolen, J. S., Wells, G., Zhang, B., van Tuyl, L. H. D., Funovits, J., Aletaha, D., Allaart, C. F., Bathon, J., Bombardieri, S., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2011.149765 · Cited by 777
Self-citationPopulation‐based assessment of adverse events associated with long‐term glucocorticoid use
Curtis, J. R., Westfall, A. O., Allison, J., Bijlsma, J. W., Freeman, A., George, V., Kovac, S. H., Spettell, C. M., & Saag, K. G. (2006) · Arthritis Care & Research · doi:10.1002/art.21984 · Cited by 595
Therapeutic Strategies for Rheumatoid Arthritis
O'Dell, J. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040226 · Cited by 588
Verstappen, S. M. M., Jacobs, J. W. G., van der Veen, M. J., Heurkens, A. H. M., Schenk, Y., ter Borg, E. J., Blaauw, A. A. M., & Bijlsma, J. W. J. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.071092 · Cited by 566
Remission and active disease in rheumatoid arthritis: Defining criteria for disease activity states
Aletaha, D., Ward, M. M., Machold, K. P., Nell, V. P. K., Stamm, T., & Smolen, J. S. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21235 · Cited by 542
Da Silva, J. A. P., Jacobs, J. W. G., Kirwan, J. R., Boers, M., Saag, K. G., Inês, L. B. S., de Koning, E. J. P., Buttgereit, F., Cutolo, M., Capell, H., et al. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.038638 · Cited by 522
Self-citationFinckh, A., Liang, M. H., van Herckenrode, C. M., & de Pablo, P. (2006) · Arthritis Care & Research · doi:10.1002/art.22353 · Cited by 492
Smolen, J. S., Han, C., Bala, M., Maini, R. N., Kalden, J. R., van der Heijde, D., Breedveld, F. C., Furst, D. E., Lipsky, P. E., & ATTRACT Study Group (2005) · Arthritis & Rheumatism · doi:10.1002/art.20982 · Cited by 462
Self-citationvan Dongen, H., van Aken, J., Lard, L. R., Visser, K., Ronday, H. K., Hulsmans, H. M. J., Speyer, I., Westedt, M., Peeters, A. J., Allaart, C. F., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22525 · Cited by 413
Self-citationSvensson, B., Boonen, A., Albertsson, K., van der Heijde, D., Keller, C., Hafström, I., & for the BARFOT Study Group (2005) · Arthritis & Rheumatism · doi:10.1002/art.21298 · Cited by 349
Self-citationEffects of glucocorticoids on radiological progression in rheumatoid arthritis
Kirwan, J. R., Bijlsma, J. W., Boers, M., & Shea, B. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006356 · Cited by 346
Self-citationMethotrexate in Rheumatoid Arthritis
(1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-2-418 · Cited by 345
Drugs Commonly Associated With Weight Change: A Systematic Review and Meta-analysis
Domecq, J. P., Prutsky, G., Leppin, A., Sonbol, M. B., Altayar, O., Undavalli, C., Wang, Z., Elraiyah, T., Brito, J. P., Mauck, K. F., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3421 · Cited by 334
Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of Care
Curtis, J. R., & Singh, J. A. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.05.044 · Cited by 326
Bakker, M. F., Jacobs, J. W. G., Welsing, P. M. J., Verstappen, S. M. M., Tekstra, J., Ton, E., Geurts, M. A. W., van der Werf, J. H., van Albada-Kuipers, G. A., Jahangier-de Veen, Z. N., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-5-201203060-00004 · Cited by 322
Wassenberg, S., Rau, R., Steinfeld, P., Zeidler, H., & Low‐Dose Prednisolone Therapy Study Group (2005) · Arthritis & Rheumatism · doi:10.1002/art.21421 · Cited by 308
Machold, K. P., Stamm, T. A., Nell, V. P. K., Pflugbeil, S., Aletaha, D., Steiner, G., Uffmann, M., & Smolen, J. S. (2006) · Rheumatology · doi:10.1093/rheumatology/kel237 · Cited by 301
Donahue, K. E., Gartlehner, G., Jonas, D. E., Lux, L. J., Thieda, P., Jonas, B. L., Hansen, R. A., Morgan, L. C., & Lohr, K. N. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-2-200801150-00192 · Cited by 299
Schett, G., Emery, P., Tanaka, Y., Burmester, G., Pisetsky, D. S., Naredo, E., Fautrel, B., & van Vollenhoven, R. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209201 · Cited by 294
Luqmani, R., Hennell, S., Estrach, C., Basher, D., Birrell, F., Bosworth, A., Burke, F., Callaghan, C., Candal-Couto, J., Fokke, C., et al. (2009) · Rheumatology · doi:10.1093/rheumatology/ken450a · Cited by 293
Boers, M., Nurmohamed, M. T., Doelman, C. J. A., Lard, L. R., Verhoeven, A. C., Voskuyl, A. E., Huizinga, T. W. J., van de Stadt, R. J., Dijkmans, B. A. C., & van der Linden, S. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.9.842 · Cited by 283
Self-citationTreatment of rheumatoid arthritis: state of the art 2009
van Vollenhoven, R. F. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.182 · Cited by 277
Treatment of rheumatoid arthritis
Gaffo, A., Saag, K. G., & Curtis, J. R. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050514 · Cited by 266
Treating rheumatoid arthritis early: A window of opportunity?
O'Dell, J. R. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10092 · Cited by 266
Glucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy
Hardy, R. S., Zhou, H., Seibel, M. J., & Cooper, M. S. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00097 · Cited by 258
Cooper, M. S., & Stewart, P. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1412 · Cited by 183
Geusens, P. P., Landewé, R. B. M., Garnero, P., Chen, D., Dunstan, C. R., Lems, W. F., Stinissen, P., van der Heijde, D. M. F. M., van der Linden, S., & Boers, M. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21896 · Cited by 182
Self-citationLubberts, E. (2010) · Seminars in Immunopathology · doi:10.1007/s00281-009-0189-9 · Cited by 173
Pain in systemic inflammatory rheumatic diseases
Atzeni, F., Masala, I. F., Salaffi, F., Di Franco, M., Casale, R., & Sarzi-Puttini, P. (2015) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2015.04.016 · Cited by 46
Low‐dose glucocorticoid therapy in rheumatoid arthritis: an obligatory therapy
Bijlsma, J. W. J., van der Goes, M. C., Hoes, J. N., Jacobs, J. W. G., Buttgereit, F., & Kirwan, J. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05342.x · Cited by 31
Metadata
- Authors
- Landewé, R. B. M., Boers, M., Verhoeven, A. C., Westhovens, R., van de Laar, M. A. F. J., Markusse, H. M., van Denderen, J. C., Westedt, M. L., Peeters, A. J., Dijkmans, B. A. C., Jacobs, P., Boonen, A., van der Heijde, D. M. F. M., & van der Linden, S.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2002-02
- Volume
- 46
- Issue
- 2
- Pages
- 347-356
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1982348705
- Cited by
- 612
- References
- 25
- FWCI
- 25.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.